focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
We donât know........itâs âsecretâ
It was lodged approx early April 2020 with the UK Intellectual Property Office.
It was described as Crystalline Formulation
When pushed at a webinar investors conference the CSO stated they could divulge details so to protect confidentiality, but did say âthe world would find out soon enoughâ.
The take on LTHâs is that this formulation allows compounds to be easily transported worldwide with great shelf life and at room temperature. It can be easily turned into soluble form for IV and back to solid crystalline.
It came after the company said at the AGM Dec 2019 that no more drug discovery would be forthcoming, then out of the blue during a global pandemic they lodge the secret patent........
GLA
Forgot my link
https://fortune.com/2021/07/05/israel-data-plunge-efficacy-pfizer-biontech-vaccine-delta-variant/amp/
Hi All
Further to my post earlier, I have been doing some reading on the Israel situation. It is very worrying.
1. Israel was hailed as a world success for vaccine rollout at speed
2. It has just reintroduced mask mandates
3. Pfizer gave approx 93% protection (2 jabs)
4. Pfizer after a single jab gave (estimated) 30-40% cover
5. The Israel government has announced that 30+% efficacy has been lost due to Delta
6. Therefore, if you had only had the single jab then you have virtually no protection from the vaccine. If you had the 2 then you are now only 60% protected.
7. The virus will mutate faster than new vaccines can keep up.
Is it any wonder the world is desperate for therapeutics.
Still have no idea what the UK govt is thinking with lifting restrictions - just check Israel out.....derrrr!!
And donât forget the other now considered more infectious variants than Delta, that being Epsilon and Lambda
Hi WIP
Iâm of the understanding that it is not the virus that is the killer, but rather individualâs immune reaction (over reaction) to it which causes Acute Respiratory Distress Syndrome (ARDS). The vaccines are now indicating less efficacy on stopping the symptoms of the virus (IMHO they have never stopped the transmission of it). So in a certain cohort of the population there is an over reaction via the immune system that leads to the cytokine storm and on set of bacterial pneumonia and ARDS. Our SDC-1801 can âswitch offâ (in simple terms) the immune over reaction. Therefore, as the virus is now showing that it can evade the vaccines via mutating then eventually everyone will again became susceptible to the virus and risk the onset of over reaction and ARDS.
GLA
Hi All
I noticed a few times yesterday on various news interviews and media posts that the UK ministers refer to covid now as endemic.
I believe that until such a time as the WHO declare itâs moved to endemic status then it will be known as pandemic.
IMHO we (the world) have only just got going on this and the pandemic will be with us all for sometime. Just look at developing countries, poor inadequate health systems, no vaccines and mass overcrowding in capital cities.......Africa and SE Asia are witnessing spiraling cases from Delta. Now add to that Delta +, Epilson and Lamda variants with each one mutating enough to evade vaccines.
As per the paper presented by the UK Government to the G7 â100 days Mission to Respondâ June 2021, the WORLD needs more than just vaccines (that are now becoming useless - case point Israel and itâs one third reduction in efficacy and countries now planning âboostersâ in an attempt to keep in front) to reach a manageable position with covid.
Therapeutics are the next massive âwarp speedâ initiative and we are in the mix.
GLA
Being reported on BBC
Running out of oxygen as delta ravages the country
Indonesia faces oxygen crisis amid worsening Covid surge https://www.bbc.co.uk/news/world-asia-57717144
Hi All
Been pondering Parkerâs tweet and I feel that his explanation of âmajor development for the UK and the worldâ could be the news that we now know that is our SDC-1801 is superior to dexamethasone.
Since itâs been a few days, we could certainly do with a Twitter update from SAR to ratify the news, as Potnak says, some slides of results from the POC experiments would be good. Come on Tim.
GLA
Hi Ade - thanks for the information, I believe this was a privately funded (charity) clinical trial commencing in late 2020/early 2021. Iâm sure if it was a success then SFX-01 would have been noted by now especially considering Q1 and Q2 the UK was grappling hard with covid. Did it receive any government funding?
ATB
Part 2
Dr David Lowe, a University College London immunologist, said: âNEW or repurposed drugs should first be carefully evaluated in small studies which establish safety and look for signs of efficacy (Sounds like preclinical and POC â that we just completed). Only those drugs which appear to be safe and efficacious should then be progressed to larger studiesâŚ.â.
IMHO â we are the NEW antiviral they are discussing here. I donât personally know of any other candidate in the UK and the UKRI trials only gave grants to a handful for proof of concept. All the signs above from late April would clearly suggest they want a âhome grownâ drug that would be a âmajor development for the UK and the World! â sounds familiar.
Finally â for the doubters â We are a âcleanâ drug that does a similar intervention as Baricitinib (a JAK inhibitor - read our patent) and we are SUPERIOR (proven) than Dexamethasone.
GLA
Hi All - another 2 part post sorry but itâs all relevant
Part 1
This is taken from the DailyMail online interviews following the 20 April announcement when Boris Johnson launched his 'ambitious' new 'antivirals taskforce' so Britons can take tablets for Covid at home 'by autumn'. I have added my humble opinion in the interview.
No drugs have been decided on but the government is already IN TALKS with pharmaceutical firms about 'PROMISING' antiviral treatments being developed, and officials are keen to get NEW drugs that aren't already used. (inconceivable that SAR are not in talks following our UKRI Grant and progress reports confirmed as witnessed by UKRI).
They are committed to finding 'NOVEL ANTIVIRAL MEDICINESâ, the Department of Health said, meaning drugs NOT currently being used by the NHS or sold commercially are being PUSHED THROUGH clinical trials over the summer. (sounds like SDC-1801)
Sir Patrick Vallance, Britain's Chief Scientific Adviser, added: âAntivirals in tablet form are another key tool for the response. The Taskforce will help ensure the MOST PROMISING antivirals are available for deployment as quickly as possible.â (now SDC-1801 is proven more SUPERIOR than Dexamethasone this certainly fits their MOST PROMISING label)
The Department of Health has refused to name any of the drugs being considered but ministers are KEEN TO GET HOLD OF A NEW, undeveloped treatment and manufacture it en masse at home in the UK.
British researchers were instrumental in âprovingâ that the steroid dexamethasone (would have been similar PROOF of CONCEPTâs as SDC-1801 â again, we are now considered SUPERIOR to dexamethasone) could cut the risk of death for seriously ill patients in hospital, and the Government is hoping UK expertise will help it find antivirals, too.
Dr Nikki Kanani, Medical Director at NHS England, added: âThere are a number of treatments AT THE MOMENT that are being TESTED and refinedâ. (was she referring the POCâs for SDC-1801)
Dr Julian Tang, a virologist at the University of Leicester, said: 'Normally you must give an antiviral within a couple of days for a respiratory virus â with the flu it is just one to two daysâ. 'Letâs say you were exposed on Saturday and not notified until Monday. By then you may have missed that window.' (this sounds very similar to what John Reader was discussing on the Investor Meet webinar).
Nice one Bobbler
Re the UK Government 100 day mission document (June 2021 - prepared for the G7), I particularly feel this extract is pertinent
* For therapeutics, there has been insufficient investment in specific and potent small molecules to treat common pathogen classes. As a result, there is an inadequate R&D ecosystem and pipeline for small molecule antivirals and âprogrammableâ antiviral platforms. Both antiviral therapeutics and vaccines take years to develop, so waiting until a pandemic threat arises is too late*
GLA
Hi All
Whitty said today - Winter is inevitably tricky and we should be realistic winter will be bad for the NHS
Timely reminder of Borisâs speech on April 20 â re Covid Pill by Autumn. He was proud to claim the UK achievement with dexamethasone in the video below.....now we know SDC-1801 is considered SUPERIOR to dexamethasone
https://news.sky.com/video/covid-19-antiviral-pills-could-stem-coronavirus-infections-says-pm-12281483
Evening All
Iâm not convinced that the UK government will drop its guard. Borisâs opening sentence is a giveaway and another sentence in the first minute is worth noting:
âSpell out what it WOULD be like IF we step downâ
âMust take careful and balanced decisionâ
He has given himself a back track - if required!
GLA
Hi all
I was having an email exchange with this guy earlier today.
Dr. Leonard Calabrese is an American rheumatologist, an osteopathic physician, and an internationally recognized HIV/AIDS and hepatitis C researcher at the Cleveland Clinic in the US
He wrote some papers in 2020 under the Cleveland Clinic - Rheumatology, Immunology and COVID-19: The Cytokine Storm and Open Trials, April 2020
https://consultqd.clevelandclinic.org/rheumatology-immunology-and-covid-19-the-cytokine-storm-and-open-trials/amp/
Based on his research and published work, I informed him about Sareum and our POC success at being superior to dexamethasone. Here is his response to me - âIâm extremely familiar with this pathway. Please point me to any publications. I am I was interested in collaborating. And I was interested in DMC work on novel trials. Look forward to hearing from youâ.
I replied and shared some links to Sareumâs patents and TYK2s publications. Also told him Stanford Research Institute were a key collaboration in the genesis of SDC-1801 & SDC-1802.
Nice feeling sharing our success and data with an internationally recognised professor.
GLA
Ran out of space......
Dr Nikita Kanani, Medical Director NHS, said:
The NHS has saved lives around the world through its contribution to developing the first ever treatment for COVID-19, dexamethasone.
The NHS has put research into reality at record speed during the pandemic and this ATF will now help us to identify and roll out even more new, convenient treatments for COVID-19.
So who still thinks whether the Government knows what we have. They are all over this via the UKRI.......IMHO wonât be long before we are confirmed as a ânovelâ therapeutic and into AGILE fast tracked in readiness for a Autumn rollout.
Sit back relax and enjoy the ride.
Hi All â is this timeline is very coincidental?
Oh and once again we are now considered SUPERIOR to dexamethasone. Our progress was being reported/observed to/by UKRI.
Antiviral Taskforce (ATF) launched 20 April
BOJO speech âpill by Autumnâ 21 April
Parkerâs tweet âmajor developmentâ 22 April (after midnight)
SAR interims RNS 23 April (7.00am)
Abstract from UK Govt press release 20 April
New ATF could identify and deploy innovative COVID-19 treatments as early as autumn
Treatments could be taken at home after a positive test or exposure to COVID-19 to reduce transmission and speed up recovery
Drugs could help combat a rise in infections or new variants over the winter flu season
The ATF will search for the most promising ânovelâ antiviral medicines that can be taken at home and support their development through clinical trials to ensure they can be rapidly rolled out to patients as early as the autumn.
The aim is to have at least 2 effective treatments this year, either in a tablet or capsule form.
Boris Johnson said:
ATF will seek to develop innovative treatments you can take at home to stop COVID-19 in its tracks. These could provide another vital defence against any future increase in infections and save more lives.
Health Secretary Matt Han***k said:
The UK is leading the world in finding and rolling out effective treatments for COVID-19, having identified dexamethasone, which has saved over a million lives worldwide, and tocilizumab.
We are now bringing together a new team that will supercharge the search for antiviral treatments and roll them out as soon as the autumn.
I am committed to boosting the UKâs position as a life science superpower and this new ATF will help us beat COVID-19.
The antivirals could be used alone or in combination with one another in order to increase effectiveness and reduce the risk of further mutations.
The new ATF will sit alongside the govtâs existing Therapeutics Taskforce, which will continue its vital work to identify and supply treatments.
Since the beginning of the pandemic, the UK has proven itself to be a world-leader in identifying and rolling out effective treatments â including the worldâs first treatment dexamethasone, which has saved 22,000 lives in the UK and an estimated million worldwide.
Sir Patrick Vallance, said:
The speed at which vaccines and therapeutics such as dexamethasone have been identified and deployed against COVID-19 has been critical to the pandemic response.
Antivirals in tablet form are another key tool for the response. They could help protect those not protected by or ineligible for vaccines. They could also be another layer of defence in the face of new variants of concern.
The ATF will help ensure the most promising antivirals are available for deployment as quickly as possible.
Dr Nikita Kanani, Medical Director NHS, said:
The NHS has saved lives around the world through its contribution to developing the first ever treatment for
Hi All - Interesting article from last Dec.
Remember our results just proved SDC-1801 is considered SUPERIOR to dexamethasone.
https://www.nytimes.com/2020/12/04/health/covid-drug-baricitinib.html
Â
Dec. 4, 2020
In mid-November, an arthritis drug with a tricky name hit a pandemic milestone â then slipped back into relative obscurity.
Â
The drug, baricitinib, was granted an emergency authorization by the FDA to treat a subset of hospitalized Covid-19 patients in combination with another medication, the antiviral remdesivir. It is one of only a handful of treatments to have earned the agencyâs green light.
Â
But baricitinibâs reception by the medical community has been lukewarm. It doesnât work all that well, for one thing, and comes with side effects, such as blood clots. And at a cost of roughly $1,500 per patient, many doctors donât know when it would make sense to use the drug, which might have overlapping roles with cheap and widely available steroids like dexamethasone.
Â
âI think itâs really a nothing burger,â said Dr. Ilan Schwartz, an infectious disease physician at the University of Alberta. âWeâre talking about adding a drug that reduces the time to clinical improvement by one day, in a disease that takes weeks to recover.â
Â
These results, which were announced through a series of news releases by drugmaker Eli Lilly, have yet to be published in a peer-reviewed scientific journal.
When an emergency authorization has been released but the data have not, doctors are caught âin a difficult place,â said Dr. Manuela Cernadas, a critical care physician in Boston. âItâs not entirely clear where this drug fits in our armamentarium of drugs weâre comfortable using.â
Â
Baricitinib is a repurposed arthritis treatment that, like a steroid, dampens inflammation, which, in severe cases of Covid-19, can spiral out of control and destroy healthy tissues. The drug acts like a molecular muffler, preventing the cells from responding to alarm signals that could make the bodyâs immune response spiral out of control.
âIt seems more incremental than blockbuster,â said Dr. Taison Bell, a critical care physician. Although Dr. Bell described baricitinib as a reasonable addition to the Covid treatment toolbox, and even deserving of an emergency approval, âI donât think itâs a game changer,â he said.
Â
But Dr. Titanji an infectious disease physician offered a more sobering perspective on dexamethasone. Steroids are âblunt knivesâ, quashing inflammation on a broader scale unlike precision therapeutic medicines like baricitinib. Still baricitinib comes with its own problems such as risks of blood clots that gives you pause Dr Cernadas said.
Both baricitinib and dexamethasone also blunt the immune function but of the two dexamethasone is âthe devil you knowâ said Dr. Lauren Henderson.
Again, SDC-1801 is considered SUPERIOR to dexamethasone and will work much better than barcitinib with its black box toxicity warnings.
GLA
Â